Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection

Neurology

Volumn 83, Issue 18, 2014, Pages 1592-1600

  Young, Andrew C ^a   Yiannoutsos, Constantin T ^b   Hegde, Manu ^c   Lee, Evelyn ^c   Peterson, Julia ^c   Walter, Rudy ^c   Price, Richard W ^c   Meyerhoff, Dieter J ^c   Spudich, Serena ^a  

^a YALE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHOLINE; CREATINE PHOSPHATE; GLUTAMIC ACID; INOSITOL; INTEGRASE INHIBITOR; N ACETYLASPARTIC ACID; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTERIOR CINGULATE; ANTIVIRAL THERAPY; ARTICLE; BASAL GANGLION; BRAIN METABOLISM; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAGNETIC FIELD; MAJOR CLINICAL STUDY; MALE; PRIMARY INFECTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; VIRUS TRANSMISSION; WHITE MATTER; BRAIN; CHRONIC DISEASE; DEVICES; DRUG EFFECTS; HIV INFECTIONS; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES;

ADULT; ANTI-RETROVIRAL AGENTS; CEREBRUM; CHRONIC DISEASE; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED;

EID: 84922393949     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000932     Document Type: Article

References (39)

1. Meyerhoff DJ, MacKay S, Poole N, Dillon WP, Weiner MW, Fein G. N-acetylaspartate reductions measured by 1H MRSI in cognitively impaired HIVseropositive individuals. Magn Reson Imaging 1994; 12:653-659.
2. Yiannoutsos CT, Ernst T, Chang L, et al. Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage 2004;23:928-935.
3. Sacktor N, Skolasky RL, Ernst T, et al. A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging 2005;21:325-333.
4. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 1999;52:100-108.
5. Meyerhoff DJ, Bloomer C, Cardenas V, Norman D, Weiner MW, Fein G. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV1 patients. Neurology 1999;52:995-991003.
6. Ernst T, Jiang CS, Nakama H, Buchthal S, Chang L. Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder. J Magn Reson Imaging 2010; 32:1045-1053.
7. Stankoff B, Tourbah A, Suarez S, et al. Clinical and spectroscopic improvement in HIV-associated cognitive impairment. Neurology 2001;56:112-115.
8. Chang L, Ernst T, Witt MD, et al. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther 2003;8:17-26.
9. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011;25:625-633.
10. Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012;206:275-282.
11. Davis LE, Hjelle BL, Miller VE, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992;42:1736-1739.
12. Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 2005;12(suppl 1): 878-892.
13. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIVassociated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75:2087-2096.
14. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24:1243-1250.
15. Lentz MR, Kim WK, Kim H, et al. Alterations in brain metabolism during the first year of HIV infection. J Neurovirol 2011;17:220-229.
16. Cinque P, Brew BJ, Gisslen M, Hagberg L, Price RW. Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex. Handb Clin Neurol 2007;85:261-300.
17. Hagberg L, Cinque P, Gisslen M, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010;7:15.
18. Peluso MJ, Meyerhoff DJ, Price RW, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 2013;207: 1703-1712.
19. Spudich S, Gisslen M, Hagberg L, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 2011;204:753-760.
20. Letendre SL, Zheng JC, Kaul M, et al. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol 2011;17:63-69.
21. Zetola NM, Pilcher CD. Diagnosis and management of acute HIV infection. Infect Dis Clin North Am 2007;21:19-48.
22. Lindback S, Thorstensson R, Karlsson AC, et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure: Karolinska Institute Primary HIV Infection Study Group. AIDS 2000;14:2333-2339.
23. Abe C, Mon A, Durazzo TC, Pennington DL, Schmidt TP, Meyerhoff DJ. Polysubstance and alcohol dependence: unique abnormalities of magnetic resonance-derived brain metabolite levels. Drug Alcohol Depend 2013;130:30-37.
24. Lindback S, Karlsson AC, Mittler J, et al. Viral dynamics in primary HIV-1 infection: Karolinska Institute primary HIV infection study group. AIDS 2000;14:2283-2291.
25. Soher BJ, Young K, Govindaraju V, Maudsley AA. Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med 1998;40:822-831.
26. Spudich SS, Nilsson AC, Lollo ND, et al. Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005;5:98.
27. Fuller RA, Westmoreland SV, Ratai E, et al. A prospective longitudinal in vivo 1H MR spectroscopy study of the SIV/macaque model of neuroAIDS. BMC Neurosci 2004;5:10-10.
28. Ratai EM, Pilkenton SJ, Greco JB, et al. In vivo proton magnetic resonance spectroscopy reveals region specific metabolic responses to SIV infection in the macaque brain. BMC Neurosci 2009;10:63.
29. Sailasuta N, Ross W, Ananworanich J, et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One 2012;7:e49272.
30. Lentz MR, Kim WK, Lee V, et al. Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology 2009;72:1465-1472.
31. Greco JB, Westmoreland SV, Ratai EM, et al. In vivo 1H MRS of brain injury and repair during acute SIV infection in the macaque model of neuroAIDS. Magn Reson Med 2004;51:1108-1114.
32. O'Donnell LA, Agrawal A, Jordan-Sciutto KL, Dichter MA, Lynch DR, Kolson DL. Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes. J Neurosci 2006;26:981-990.
33. Erdmann NB, Whitney NP, Zheng J. Potentiation of excitotoxicity in HIV-1 associated dementia and the significance of glutaminase. Clin Neurosci Res 2006;6: 315-328.
34. Wang Z, Pekarskaya O, Bencheikh M, et al. Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. Virology 2003;312:60-73.
35. Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 2007;48:166-172.
36. Ances BM, Sisti D, Vaida F, et al. Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 2009;73:702-708.
37. Ernst T, Itti E, Itti L, Chang L. Changes in cerebral metabolism are detected prior to perfusion changes in early HIV-CMC: a coregistered (1)H MRS and SPECT study. J Magn Reson Imaging 2000;12:859-865.
38. Schifitto G, Deng L, Yeh TM, et al. Clinical, laboratory, and neuroimaging characteristics of fatigue in HIVinfected individuals. J Neurovirol 2011;17:17-25.
39. Crum-Cianflone NF, Moore DJ, Letendre S, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology 2013;80:371-379.